http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0502113-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5db6243e0edb49c2d3e7af3f5580b7fd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-805 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-805 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-08 |
| filingDate | 1990-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac122fade3725f6e9476a9dcf516eaed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fab7b5e6f870b1563cf2feb99a8ae81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c181bbada12e873540dc08f8565ebd5 |
| publicationDate | 1992-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0502113-A1 |
| titleOfInvention | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
| abstract | Chemically modified hemoglobin produced by a new and efficient process in which the stroma-free hemoglobin is first deoxygenated and reduced effectively, then is conjugated to a polyalkylene oxide such as polyethylene glycol (PEG) under conditions which maintain structural integrity of the heme oxygen binding site. In specific preferred embodiments of the invention, deoxygenation and reduction take place in an inert atmosphere using the amino acid cysteine. In other specific preferred embodiments, the structural integrity of the heme oxygen binding site is maintained by a high anionic concentration in the reaction mixture. According to other preferred, specific embodiments of the invention, the polyalkylene oxide is polyethylene glycol; other specific preferred embodiments of the invention provide that the polyalkylene oxide is linked to hemoglobin via a urethane (carbamate) bond. The new hemoglobin compounds modified with PEG of the invention have superior oxygen transport capacities, a prolonged half-life, and in particular a low immunogenicity. |
| priorityDate | 1989-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 227.